EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone‐sensitive prostate cancer; KYUCOG ‐1401

Akira Yokomizo iD, Masaki Shiota iD, Futoshi Morokuma, Masatoshi Eto, Hideyasu Matsuyama, Hiroaki Matsumoto iD, Toshiyuki Kamoto, Naoki Terada iD, Kazuya Kawahara, Hideki Enokida, Shuichi Tatarano, Naohiro Fujimoto iD und 9 weitere

International Journal of Urology · 2024

DOI: 10.1111/iju.15371 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Urology, 2024. Verfasst von Akira Yokomizo und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Harasanshin Hospital, Fukuoka, Japan. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Astellas Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To compare the effectiveness and safety of gonadotropin‐releasing hormone (GnRH) antagonist monotherapy to combined androgen blockade (CAB) with a GnRH agonist and bicalutamide in patients with advanced hormone‐sensitive prostate cancer (HSPC).

Methods

The study was conducted as KYUCOG‐1401 trial (UMIN000014243) and enrolled 200 patients who were randomly assigned to either group A (GnRH antagonist monotherapy followed by the addition of bicalutamide) or group B (CAB by a GnRH agonist and bicalutamide). The primary endpoint was PSA progression‐free survival. The secondary endpoints were the time to CAB treatment failure, radiographic progression‐free survival, overall survival, changes in serum parameters, including PSA, hormones, and bone and lipid metabolic markers, and adverse events.

Results

PSA progression‐free survival was significantly longer in group B (hazard ratio [HR], 95% confidence interval [CI]; 1.40, 1.01–1.95, p = 0.041). The time to CAB treatment failure was slightly longer in group A (HR, 95% CI; 0.80, 0.59–1.08, p = 0.146). No significant differences were observed in radiographic progression‐free survival or overall survival. The percentage of patients with serum testosterone that did not reach the castration level was higher at 60 weeks ( p = 0.046) in group A. No significant differences were noted in the serum levels of bone metabolic or lipid markers between the two groups. An injection site reaction was more frequent in group A.

Conclusions

The present results support the potential of CAB using a GnRH agonist and bicalutamide as a more effective treatment for advanced HSPC than GnRH antagonist monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic NeoplasmsMaleHumansAndrogen AntagonistsAntineoplastic Combined Chemotherapy ProtocolsAnilidesNitrilesTosyl CompoundsGonadotropin-Releasing HormoneLipids

Stichwörter der Autor:innen

GnRH agonistGnRH antagonistcombined androgen blockademetastatic hormone‐sensitive prostate cancerrandomized controlled trial

Substanzen

bicalutamideProstate-Specific AntigenAndrogen AntagonistsAnilidesNitrilesTosyl CompoundsGonadotropin-Releasing HormoneLipids

Autor:innen und Institutionen

  • Department of Urology, Harasanshin Hospital, Fukuoka, Japan.
  • Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Urology Department, Saga-Ken Medical Centre Koseikan, Saga, Japan.
  • Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.
  • Department of Urology, University of Miyazaki, Miyazaki, Japan.
  • Department of Urology, University of Fukui, Fukui, Japan.

ORCID-Profile: Akira Yokomizo, Masaki Shiota, Hiroaki Matsumoto, Naoki Terada, Naohiro Fujimoto, Shigetaka Suekane

Förderung

  • Astellas Pharma

Zitieren

APA

Yokomizo, A., Shiota, M., Morokuma, F., Eto, M., Matsuyama, H., Matsumoto, H., Kamoto, T., Terada, N., Kawahara, K., Enokida, H., Tatarano, S., Fujimoto, N., Higasijima, K., Sakai, H., Hakariya, T., Igawa, T., Suekane, S., Kamba, T., Sugiyama, Y., …, & Naito, S. (2024). GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone‐sensitive prostate cancer; KYUCOG ‐1401. International Journal of Urology. https://doi.org/10.1111/iju.15371

Vancouver

Yokomizo A, Shiota M, Morokuma F, Eto M, Matsuyama H, Matsumoto H, et al. GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone‐sensitive prostate cancer; KYUCOG ‐1401. International Journal of Urology. 2024. doi:10.1111/iju.15371

BibTeX
@article{Yokomizo2024,
  author = {Yokomizo, Akira and Shiota, Masaki and Morokuma, Futoshi and Eto, Masatoshi and Matsuyama, Hideyasu and Matsumoto, Hiroaki and Kamoto, Toshiyuki and Terada, Naoki and Kawahara, Kazuya and Enokida, Hideki and Tatarano, Shuichi and Fujimoto, Naohiro and Higasijima, Katsuyoshi and Sakai, Hideki and Hakariya, Tomoaki and Igawa, Tsukasa and Suekane, Shigetaka and Kamba, Tomomi and Sugiyama, Yutaka and Kishimoto, Junji and Naito, Seiji},
  title = {GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone‐sensitive prostate cancer; KYUCOG ‐1401},
  journal = {International Journal of Urology},
  year = {2024},
  doi = {10.1111/iju.15371}
}
Kostenlos starten →